

CERTIFICATE OF ANALYSIS

Lot#: NHM2355-HE-N

PRODUCT DESCRIPTION

Reference: HuHECPMI/6+**Product:** Cryopreserved Human Hepatocytes**Category:** Plateable, Cytochrome P450 inducible**Spheroid qualified:** Yes**Specific culture requirements:** Yes***Storage conditions:** -196°C using LN₂**Sterility test:** negative for mycoplasma, bacteria, yeast, and fungi


DONOR DEMOGRAPHICS

| Species | Gender | Race | Age | BMI | HLA | Smoker | Alcohol Use | Drug Use | COD |
|---------|--------|-----------|-----------|------|------------------------------|--------|-------------|----------|----------|
| Human | Female | Caucasian | 17 months | 19.2 | A02, A03, B07, B51, C07, C15 | No | No | No | Drowning |

Patient informed consent was obtained. The donor was serologically tested negative for following infectious diseases: HIV, Hepatitis B and C, syphilis, CMV, and EBV.

CHARACTERIZATION FOR PLATEABLE CELLS

| Post Thaw Lot information | Result | SD | n |
|---|----------------------|------------------------|---|
| Number of viable cells (cells/vial): | 7.64x10 ⁶ | ± 1.58x10 ⁶ | 3 |
| Post-thaw viability (%): | 92.15 | ± 1.63 | 3 |
| Days in culture after thaw (24w): | >11 | ± 0.00 | 1 |
| Days in culture after thaw (96w): | >11 | ± 0.00 | 1 |

MONOLAYER ASSESSMENT¹ Plateable: YES**Confluence 24h: 95%****Seeding density in 24 well recommended:**2.10x10⁵ cells/cm²**Seeding density in 96 well recommended:**2.81x10⁵ cells/cm²

Human hepatocytes were thawed and seeded according to BeCytes Biotechnologies culture no spin protocol. The yield and viability were determined by a trypan blue exclusion assay after the thawing process. ¹Resuspended human hepatocytes from post-thaw assessment were plated in collagen-coated 24-well plates in hepatocyte plating medium. Cells were refreshed with hepatocytes maintenance medium the day after thawing. Maintenance medium was replaced in the culture every day. If images from the 96-well plates are needed, please contact us.


*** TO OBTAIN THE RESULTS DESCRIBED ABOVE, PLEASE FOLLOW THE NO SPIN PROTOCOL PROVIDED BY BECYTES**

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.

CYTES BIOTECHNOLOGIES, SL.

Parc Científic de Barcelona, C/Baldiri Reixac 4-8 | www.becytes.com | info@cytesbiotech.com | P.+34 934034553

3D SPHEROID FORMATION



Primary human hepatocytes self-assembled into a spheroid containing 5000 cells after 5 days in culture. These hepatic spheroids were cultured for 7-15 days in ultra-low attachment (ULA) plates with our 3D Culture Maintenance Media for hepatocytes (MHM3D). *For more information/protocols about 3D hepatocyte spheroids, contact us.*

INDUCTION FOR PLATEABLE CELLS

PHASE I: CYP ACTIVITIES EXPRESSED IN pmol/min/mg protein (mean ± SD)

| Enzyme | Induction (Specific Activity) | | | |
|--------|-------------------------------|-------------------------|---------------------------|------------------|
| | Basal Activity on day 1 | Basal Activity on day 4 | Induced Activity on day 4 | n-Fold induction |
| CYP1A2 | 6.11 ± 0.33 | 9.28 ± 0.76 | 132.67 ± 27.01 | 14.29 |
| CYP2B6 | 5.98 ± 1.36 | 8.36 ± 0.67 | 28.11 ± 3.23 | 3.36 |
| CYP3A4 | 19.17 ± 4.55 | 36.01 ± 5.84 | 88.88 ± 24.49 | 2.47 |

Cryopreserved human hepatocytes were thawed and plated in 24well collagen I coated plates. Cells were overlaid with Matrigel® (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. Treatment (n=2 per compound) with vehicle control [0.15% (v/v) DMSO] or inducers (Rifampicin, β-Naphthoflavone and Phenobarbital) began 1-day post-plating and continued for 72 hours. At the end of induction, monolayers were rinsed with PBS and incubated with probe substrate solutions in culture media. See Table 1 for information on each probe substrate. Metabolites were quantified by LC-MS and normalized to protein content. The fold induction was calculated by dividing the induced activity by the vehicle basal activity on the same day in culture.

PHASE I: CYP450 mRNA induction

| CYP (mRNA) | n-Fold Induction |
|------------|------------------|
| CYP1A2 | 29 ± 12 |
| CYP2B6 | 5 ± 2 |
| CYP3A4 | 4 ± 1 |

Cryopreserved human hepatocytes were thawed, plated in 24well collagen I coated plates in Hepatocyte Plating Medium. Cells were overlaid with Matrigel® (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. Maintenance medium was replaced in the cultures daily. Treatment (n=2 per compound) with vehicle control [0.15% (v/v) DMSO] or inducers (Rifampicin, β-Naphthoflavone and Phenobarbital) began 1-day post-plating and continued for 72 hours. At the end of the treatment period, RNA was isolated for mRNA analysis.

Table 1. Substrates Phase I

| Enzyme | Probe Substrate | Concentration (μM) | Incubation Time (min) | Metabolite |
|--------|-----------------|--------------------|-----------------------|--------------------|
| CYP1A2 | Phenacetin | 100 | 30 | Acetaminophen |
| CYP2B6 | Bupropion | 500 | 30 | Hydroxybupropion |
| CYP3A4 | Midazolam | 30 | 30 | 1-Hydroxymidazolam |

PHASE II: UGTs & SULT ACTIVITIES 24h AFTER SEEDING EXPRESSED IN pmol/min/mg PROTEIN (mean ± SD)

| Enzyme | Conjugate | pmol/min/mg |
|--------|---------------------------|----------------|
| UGT | 7-OH coumarin glucuronide | 701.79 ± 10.64 |
| SULT | 7-OH coumarin sulfate | 28.94 ± 0.07 |

Cryopreserved human hepatocytes were thawed, plated in 24well collagen I coated plates in Hepatocyte Plating Medium. Cells were overlaid with Matrigel® (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. On day 1, hepatocytes were incubated with 7-Hydroxycoumarin to assay for UDP-Glucuronosyltransferase (UGT) and Sulfotransferase (SULT) activities. See Table 2 for information on each probe substrate. Metabolites were quantified by LC-MS and normalized to protein content.

Table 2. Substrates Phase II



| Enzyme | Probe Substrate | Concentration (μM) | Incubation Time (min) | Metabolite |
|--------|-------------------|--------------------|-----------------------|-------------------------------|
| UGT | 7-Hydroxycoumarin | 100 | 30 | 7-Hydroxycoumarin-glucuronide |
| SULT | 7-Hydroxycoumarin | 100 | 30 | 7-Hydroxycoumarin-sulfate |

If you need help for an experiment, just contact us, our experts will be pleased to assist you

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.

CERTIFICATION:

The viability and performance of the primary human hepatocytes provided depend primarily on the use of appropriate media and reagents, as well as the use of sterile plastics. Likewise, proper handling protocols must be followed. Please note that if these parameters are not carefully considered, the cellular response obtained in the assays may be lower than expected.

| Name | Title | Signature | Cytes Biotechnologies, S.L. | Date |
|------------------------|-----------------|---|---|----------|
| Pilar Sainz de la Maza | Quality Manager |  |  | 27/02/24 |

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.

CELL COUNTING


Lot #: _____

Date: ____/____/____

MORPHOLOGY

- Clear cytoplasm
- Rounded shape
- Cell swelling
- Hardly any debris
- Clear membranes
- Membrane blebbing
- Lipid droplets
- Prevalent debris

TRYPAN BLUE COUNTING RESULTS



| NEUBAUER CHAMBER COUNTING | | | | | |
|---------------------------|------------|---|------------|---|-------------|
| Quadrant | Live cells | + | Dead cells | = | Total cells |
| Quadrant 1 | | + | | = | |
| Quadrant 2 | | + | | = | |
| Quadrant 3 | | + | | = | |
| Quadrant 4 | | + | | = | |
| Total | | + | | = | |

VIABILITY

$$\frac{(\text{Live cells})}{(\text{Total cells})} \times 100 = \text{Viability (\%)}$$

YIELD

$$\frac{(\text{Total cells}) \times (\text{Dilution factor}) \times 10^4 \times (\text{Current volume}) \text{ ml}}{(\text{Counted quadrants})} = \text{cells (Total number of cells)}$$

**This factor (10⁴) is applicable when it is used a Hemocytometer*

SEEDING DENSITY

$$\frac{(\text{Desired number of cells})}{(\text{Total number of cells})} \times \frac{\text{cells} \times (\text{Current volume}) \text{ ml}}{\text{cells}} = \text{ml (Volume needed for your cells)}$$

Keep in mind the final volume per dish or plate to use (Volume needed) and then calculate the needed volume to add: $(\text{Total volume well}) \text{ ml} - (\text{Cells total volume}) \text{ ml} = \text{ml (Volume to add)}$

Surface of the most common plates for culture:

| Brand | 24-well plate | 96-well plate |
|--------------|----------------------------|----------------------------|
| ThermoFisher | 1.90 cm ² /well | 0.32 cm ² /well |
| Corning® | 2.00 cm ² /well | 0.36 cm ² /well |
| Falcon® | 1.90 cm ² /well | 0.32 cm ² /well |
| Eppendorf | 2.08 cm ² /well | 0.37 cm ² /well |

COMMENTS

COUNTED BY:

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCYtes Biotechnologies may contain human material that should be treated as potentially biohazardous.